Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.06 | Insider Own | 44.54% | Shs Outstand | 27.39M | Perf Week | -3.92% |
| Market Cap | 1.22B | Forward P/E | 21.83 | EPS next Y | 2.04 | Insider Trans | -3.48% | Shs Float | 21.05M | Perf Month | 19.47% |
| Enterprise Value | 1.21B | PEG | 68.38 | EPS next Q | - | Inst Own | - | Short Float | 5.83% | Perf Quarter | 43.78% |
| Income | -1.47M | P/S | 14.05 | EPS this Y | 1532.50% | Inst Trans | - | Short Ratio | 2.98 | Perf Half Y | 210.80% |
| Sales | 86.93M | P/B | 39.75 | EPS next Y | 137.74% | ROA | -1.51% | Short Interest | 1.23M | Perf YTD | 163.75% |
| Book/sh | - | P/C | 76.83 | EPS next 5Y | 64.43% | ROE | -5.68% | 52W High | 49.42 -11.12% | Perf Year | 192.27% |
| Cash/sh | - | P/FCF | 79.17 | EPS past 3/5Y | - | ROIC | 3.10% | 52W Low | 14.05 212.54% | Perf 3Y | 1475.97% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 56.18% - | Gross Margin | 54.77% | Volatility | 5.27% 6.05% | Perf 5Y | 767.70% |
| Dividend TTM | - | EV/Sales | 13.97 | EPS Y/Y TTM | 60.00% | Oper. Margin | 2.35% | ATR (14) | 2.40 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.88 | Sales Y/Y TTM | 120.51% | Profit Margin | -1.70% | RSI (14) | 57.95 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.21 | EPS Q/Q | -28.57% | SMA20 | 2.80% | Beta | 0.85 | Target Price | 59.67 |
| Payout | 0.00% | Debt/Eq | 0.40 | Sales Q/Q | 41.18% | SMA50 | 19.88% | Rel Volume | 0.61 | Prev Close | 44.60 |
| Employees | 44 | LT Debt/Eq | 0.85 | Earnings | Aug 13 | SMA200 | 83.35% | Avg Volume | 455.44K | Price | 43.93 |
| IPO Date | Nov 14, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -55.88% 8.76% | Net Debt/EBITDA | -1.36 | Volume | 277,124 | Change | -1.51% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Reiterated | Craig-Hallum | Buy | $15 → $62 |
| Jul-16-26 | Initiated | Canaccord | Buy | $60 |
| May-15-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $57 |
| May-29-25 | Reiterated | HC Wainwright & Co. | Buy | $11 → $35 |
| Oct-28-24 | Reiterated | Craig-Hallum | Buy | $8.00 → $15 |
| Oct-04-24 | Reiterated | HC Wainwright & Co. | Buy | $9.00 → $11 |
| May-06-24 | Initiated | Craig-Hallum | Buy | $8.00 |
| Jul-25-22 | Reiterated | HC Wainwright & Co. | Buy | $9.00 |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 86 | 80 | 39 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 40 | 37 | 16 | — | — | — | — | — | — | |
| Gross Profit | 48 | 43 | 23 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 37 | 36 | 23 | — | — | — | — | — | — | |
| Research and Development | 9 | 8 | 3 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | -1 | 0 | — | — | — | — | — | — | |
| Operating Income | 2 | 0 | -3 | — | — | — | — | — | — | |
| Interest Expense | 2 | 5 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | 0 | 1 | — | — | — | — | — | — | |
| Net Income Before Taxes | -2 | -5 | -4 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -2 | -5 | -4 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -2 | -5 | -4 | — | — | — | — | — | — | |
| Net Income | -2 | -5 | -4 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.05 | -0.17 | -0.15 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.05 | -0.17 | -0.15 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.06 | -0.17 | -0.15 | — | — | — | — | — | — | |
| EBITDA | 6 | 4 | -1 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.79 | 5.71 | 8.88 | — | — | — | — | — | — | |
| Gross Margin | 55.81 | 53.75 | 58.97 | — | — | — | — | — | — | |
| Operating Margin | 2.33 | 0.00 | -7.69 | — | — | — | — | — | — | |
| Net Margin | -2.33 | -6.25 | -10.26 | — | — | — | — | — | — | |
| Shares Outstanding | 27 | 27 | 26 | — | — | — | — | — | — | |
| Market Capitalization | 1,186 | 457 | 346 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner | Jul 14 '26 | Sale | 37.54 | 28,315 | 1,063,033 | 40,000 | Jul 16 |
| BRYNJELSEN SEAN | President & CEO | Jul 14 '26 | Option Exercise | 1.37 | 400,000 | 548,000 | 1,061,194 | Jul 14 |
| BRYNJELSEN SEAN | President & CEO | Jul 12 '26 | Option Exercise | 0.00 | 27,500 | 0 | 861,194 | Jul 14 |
| Krempa David | Chief Business Officer | Jul 12 '26 | Option Exercise | 0.00 | 10,000 | 0 | 37,025 | Jul 13 |
| Opaleye Management Inc. | 10% Owner | Jul 07 '26 | Sale | 38.37 | 26,685 | 1,023,978 | 53,315 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 06 '26 | Sale | 38.00 | 10,000 | 380,000 | 2,700,000 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 02 '26 | Sale | 37.39 | 90,000 | 3,364,660 | 60,000 | Jul 07 |
| Adams Jennifer McKie | Director | Jun 17 '26 | Option Exercise | 3.78 | 50,000 | 189,000 | 50,000 | Jun 17 |
| Adams Jennifer McKie | Director | Jun 17 '26 | Sale | 32.48 | 50,000 | 1,623,795 | 0 | Jun 17 |
| BRYNJELSEN SEAN | President & CEO | May 28 '26 | Sale | 31.88 | 120,000 | 3,825,717 | 833,694 | May 29 |
| Krempa David | Chief Business Officer | May 27 '26 | Sale | 31.47 | 19,679 | 619,375 | 25,249 | May 27 |
| Krempa David | Chief Business Officer | May 27 '26 | Option Exercise | 2.18 | 19,679 | 42,879 | 44,928 | May 27 |
| Krempa David | Chief Business Officer | May 26 '26 | Sale | 31.49 | 37,524 | 1,181,732 | 25,249 | May 27 |
| Krempa David | Chief Business Officer | May 26 '26 | Option Exercise | 1.38 | 37,524 | 51,658 | 62,773 | May 27 |
| Krempa David | Chief Business Officer | May 22 '26 | Option Exercise | 3.58 | 30,591 | 109,516 | 68,046 | May 27 |